Genomic Precision

 A SeraCare blog focused on precision medicine and advanced clinical diagnostics

Customer Data: Use of Seraseq ctDNA Reference Samples to Validate Detection of Low Frequency Variants in a cfDNA-based NGS Lung Cancer Panel

Posted by Omo Clement, Ph.D. on Feb 14, 2019 2:10:00 PM

At the recently-concluded 2018 AMP Meeting, researchers at the New York Presbyterian Hospital (NYPH) and Weill Cornell Medical Center (WCMC) presented a poster1 on the validation of an Oncomine™ cell-free DNA Lung Assay using ctDNA NGS standards developed by SeraCare (Seraseq® ctDNA v2 Reference Materials),2

Read More

Topics: ctDNA, SeraSeq, cfDNA, #AMP2018, New York Presbyterian Hospital, Weill Cornell Medical Center

Keys to Better Liquid Biopsy Assay Sensitivity – AMP Corporate Workshop Video

Posted by Sam Blier on Jan 24, 2019 10:30:00 AM

“So as everyone here is aware, I’m sure, detection of circulating tumor DNA is challenging. There’s very little of it, to start with.” Hardly a revolutionary statement by Tony Godfrey, PhD, (Associate Chair, Surgical Research and Associate Professor of Surgery, Boston University School of Medicine) but an important acknowledgement from a leading expert of the difficulty faced by laboratorians

Read More

Topics: ctDNA, NGS reference materials, #AMP2018

Tips for Better EGFR Mutation Testing

Posted by Catherine Huang on Jan 10, 2019 11:30:00 AM

Tips for Better EGFR Mutation Testing

Molecular testing of genomic alterations in the EGFR gene is critical to personalized treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). However, the testing landscape is complex. Some mutations confer sensitivity, and others confer resistance to anti-EGFR targeted therapies.

Read More

Topics: ctDNA, SeraSeq, Ffpe, EGFR

Two Must-See Liquid Biopsy Poster Videos From AMP 2018

Posted by Sam Blier on Dec 7, 2018 2:19:00 PM

 

Of the many fantastic posters presented at AMP’s Annual Meeting in San Antonio, two concerning NGS-based liquid biopsy assays stood out. Both presenters described how their organizations are working to reliably detect pathogenic variants at extremely low allele frequencies – efforts critical to the clinical adoption of NGS-based liquid biopsy assays.

Read More

Topics: ctDNA, SeraSeq, cfDNA, #AMP2018

How A New Generation of ctDNA Reference Standards Are Enabling the Promise of Precision Medicine

Posted by Omo Clement, Ph.D. on Jun 14, 2018 10:00:00 AM

An important goal in cancer disease management is early detection. When detected early, disease progression can be significantly mitigated with a plethora of options (targeted therapy, chemotherapy, surgery, etc.) available to medical practitioners, to afford progression free survival and a higher quality of life. A great promise of liquid biopsies is the possibility of early detection of cancer long before clear evidence of lesions and tumor growth observable by imaging or other techniques.1 As proxy for solid tissue biopsies, plasma-based liquid biopsy application is rapidly gaining traction in cancer disease diagnosis, progression, monitoring, and in predicting resistance to treatment options.2

Read More

Topics: ctDNA, SeraSeq, NGS assays, liquid biopsy, ccfDNA, NGS reference materials, Clinical NGS Assays, Lung Cancer, colon cancer

Sensitive ctDNA Assays are Required for Minimal Residual Cancer Detection

Posted by Russell Garlick on May 29, 2018 3:10:00 PM

The 11th International Symposium on Minimal Residual Cancer was held this month and much of the conference was devoted to new minimally invasive methods for circulating tumor cell enrichment and or the analysis of circulating tumor DNA. Today’s clinical needs are to measure disease burden, track mutations over time, or to detect early resistance and all of these applications require extremely sensitive, robust assays.

Read More

Topics: ctDNA, SeraSeq, DNA

An Efficient and Ultrasensitive NGS Solution for Profiling ctDNA [Poster Talk Video]

Posted by Trevor Brown on Mar 5, 2018 8:28:14 AM

SeraCare Customer Poster Talk Video with Data Presented by Asuragen

Next-generation sequencing (NGS) of liquid biopsies offers a minimally invasive alternative to solid tissue biopsies and a more holistic profile of intra- and inter-tumoral heterogeneity for therapy selection and disease monitoring. 

Watch the video and download this free poster to learn:
Read More

Topics: ctDNA, NGS assays, liquid biopsy, next gen sequencing, NGS reference materials

Accelerating Liquid Biopsy Assay Development

Session Summary from Next Generation Dx Summit 2017

Posted by Sam Blier on Sep 8, 2017 11:15:00 AM

At the 2017 Next Generation Dx Summit in Washington, DC, our CSO, Russell Garlick, PhD, presented a workshop on accelerating liquid biopsy assay development. He has worked closely with a variety of groups in the liquid biopsy space that are developing and validating circulating tumor DNA (ctDNA) assays. He highlighted some common challenges facing the field, and explained how SeraCare has been using these collaborations to develop QC tools specifically for ensuring the robustness of these cutting-edge tests.

Read More

Topics: ctDNA, liquid biopsy, assay development, circulating tumor DNA reference Materials, circulating cell-free DNA, biosynthetic reference materials, assay performance, 2017 Next Generation Dx Summit

Three liquid biopsy problems solved by the most patient-like ctDNA reference materials

SeraCare’s new Seraseq™ Circulating Tumor Reference Materials

Posted by Dale Yuzuki on Jul 24, 2017 10:00:00 AM

Clinical genomics laboratories are increasingly looking to liquid biopsy cancer assays to complement their current solid tumor assays. Compared to their solid tumor assay counterparts, circulating tumor DNA (ctDNA) assays offer a different set of challenges to consider for clinical labs.  One of the most important of which, is to develop a set of reagents that are appropriately validated to determine the critical performance of the assay across many parameters.  The ctDNA targets of liquid biopsy assays are typically at much lower allelic frequencies and require a robust and reproducibly designed assay to consistently detect these important variants.

Read More

Topics: Circulating Tumor DNA, ctDNA, Reference Material, DNA, patient-like, cell free DNA, cfDNA, DNA Blend

How Many Target Copies Are Present in Your Plasma DNA Sample?

A 0.1% measurement requires a reasonable amount of input material

Posted by Dale Yuzuki on Jun 15, 2017 1:30:00 PM

The field of circulating tumor DNA analysis (ctDNA, also sometimes called in a larger context “liquid biopsy”) holds great promise for monitoring response to cancer treatment, assisting therapeutic choice, monitoring recurrence, and for pre-cancer screening. As such there is a great amount of assay development and ongoing clinical trials; at ClinicalTrials.gov searching for the term "Circulating DNA" you can find over 180 open clinical trials for a wide range of tumor types and interventions.

Read More

Topics: Cancer, Circulating Tumor DNA, ctDNA, liquid biopsy, plasma DNA Sample, ccfDNA, assay development

 
 
ebook CTA image square Jan2019

Subscribe for Updates

Recent Posts

Categories

see all